Medivir AB (ST:MVIR) — Market Cap & Net Worth
Market Cap & Net Worth: Medivir AB (MVIR)
Medivir AB (ST:MVIR) has a market capitalization of $22.98 Million (Skr213.57 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #24596 globally and #489 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medivir AB's stock price Skr1.90 by its total outstanding shares 112167805 (112.17 Million).
Medivir AB Market Cap History: 2015 to 2026
Medivir AB's market capitalization history from 2015 to 2026. Data shows change from $649.21 Million to $22.98 Million (-28.17% CAGR).
Medivir AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medivir AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MVIR by Market Capitalization
Companies near Medivir AB in the global market cap rankings as of May 4, 2026.
Key companies related to Medivir AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Medivir AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Medivir AB's market cap moved from $649.21 Million to $ 22.98 Million, with a yearly change of -28.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr22.98 Million | +365.53% |
| 2025 | Skr4.94 Million | -85.60% |
| 2024 | Skr34.28 Million | -0.35% |
| 2023 | Skr34.40 Million | -71.21% |
| 2022 | Skr119.50 Million | -11.61% |
| 2021 | Skr135.20 Million | +64.34% |
| 2020 | Skr82.27 Million | -33.07% |
| 2019 | Skr122.90 Million | -48.23% |
| 2018 | Skr237.38 Million | -50.41% |
| 2017 | Skr478.73 Million | -50.71% |
| 2016 | Skr971.33 Million | +49.62% |
| 2015 | Skr649.21 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Medivir AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.98 Million USD |
| MoneyControl | $22.98 Million USD |
| MarketWatch | $22.98 Million USD |
| marketcap.company | $22.98 Million USD |
| Reuters | $22.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medivir AB
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phas… Read more